BTKi Therapy for CLL and MCL: EHA 2022
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

Released: July 21, 2022

Expiration: July 20, 2023

Othman Al-Sawaf
Othman Al-Sawaf, MD
Lydia Scarfò
Lydia Scarfò, MD

Activity

Progress
1
Course Completed

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

  • GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
  • FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
  • BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
  • SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL